Sleep Disorders: Sleep Disorders III |

Endocan: A Novel Predictor of Endothelial Dysfunction in Obstructive Sleep Apnea Syndrome FREE TO VIEW

Asiye Kanbay, MD; Erkan Ceylan, MD; Mustafa Caliskan, MD; Ozge Telci, MD; Osman Kostek, MD; Aybala Erek, MD; Handan Inonu, MD
Author and Funding Information

Istanbul Medeniyet University, Istanbul, Turkey

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A588. doi:10.1016/j.chest.2016.02.613
Text Size: A A A
Published online

SESSION TITLE: Sleep Disorders III

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Obstructive sleep apnea syndrome (OSAS) is an independent risk factor for endothelial dysfunction and cardiometabolic diseases. Plasma endocan levels are elevated in a large number of diseases, and is a novel surrogate endothelial cell dysfunction marker. We aimed to assess the role of serum endocan level as a potential mechanism of endothelial dysfucntion in a nonselected cohort of OSAS patients.

METHODS: This was a cohort study in which patients who had undergone a sleep study for diagnosis of OSAS were recruited. Included patients were grouped according to apnea-hypopnea index (AHI) as mild, moderate and severe OSA. Patients with AHI<5 served as control group. Endothelial function was evaluated with flow-mediated dilatation (FMD). Plasma endocan level was measured for all patients. Cardiometabolic morbid conditions were defined according to prior history and an established diagnosis of coronary artery disease, cerebrovascular accident, congestive heart failure due to coronary artery disease and arrhythmias.

RESULTS: 128 individuals included (15 controls, 22 with mild, 22 with moderate, and 69 with severe OSAS). The mean age was 51.6 ±11.9 years and 56.3% (72/128) of the study population was male. As expected, the prevalence of hypertension, diabetes and cardiovascular disease increased as the severity of OSAS increased. Endocan levels were significantly higher and FMD measurements were lower in patients with OSA compared to healthy controls. There was a positive correlation between AHI and serum endocan levels (r=0.73, p<0.0001) and there was a negative correlation between AHI and FMD (r= -0.57, p<0.0001). In addition, we observed a strong negative correlation between serum endocan level and FMD (r= -0.62, p<0.0001).

CONCLUSIONS: Serum endocan level is strongly associated with the severity of OSAS and endothelial dysfunction. Endocan might be a useful early novel marker for premature vascular endothelial system damage in OSAS patients.

CLINICAL IMPLICATIONS: OSAS might be a new etiological factor for osteoarthritis.

DISCLOSURE: The following authors have nothing to disclose: Asiye Kanbay, Erkan Ceylan, Mustafa Caliskan, Ozge Telci, Osman Kostek, Aybala Erek, Handan Inonu

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543